company background image
4168 logo

GlycoNex Incorporation TPEX:4168 Stock Report

Last Price

NT$24.60

Market Cap

NT$2.7b

7D

-0.6%

1Y

-21.9%

Updated

27 Mar, 2024

Data

Company Financials

4168 Stock Overview

GlycoNex Incorporation engages in the development of cancer drugs using glycosphingolipid antigen and human monoclonal antibody technologies in Taiwan.

4168 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

GlycoNex Incorporation Competitors

Price History & Performance

Summary of all time highs, changes and price drops for GlycoNex Incorporation
Historical stock prices
Current Share PriceNT$24.60
52 Week HighNT$34.45
52 Week LowNT$24.15
Beta0.93
1 Month Change-9.72%
3 Month Change-13.07%
1 Year Change-21.90%
3 Year Change-20.13%
5 Year Change6.96%
Change since IPO-49.13%

Recent News & Updates

Recent updates

Here's Why We're Not At All Concerned With GlycoNex Incorporation's (GTSM:4168) Cash Burn Situation

Mar 26
Here's Why We're Not At All Concerned With GlycoNex Incorporation's (GTSM:4168) Cash Burn Situation

We're Interested To See How GlycoNex Incorporation (GTSM:4168) Uses Its Cash Hoard To Grow

Dec 11
We're Interested To See How GlycoNex Incorporation (GTSM:4168) Uses Its Cash Hoard To Grow

Shareholder Returns

4168TW BiotechsTW Market
7D-0.6%-0.5%1.1%
1Y-21.9%-21.7%26.7%

Return vs Industry: 4168 matched the TW Biotechs industry which returned -21.7% over the past year.

Return vs Market: 4168 underperformed the TW Market which returned 26.7% over the past year.

Price Volatility

Is 4168's price volatile compared to industry and market?
4168 volatility
4168 Average Weekly Movement3.3%
Biotechs Industry Average Movement4.3%
Market Average Movement4.2%
10% most volatile stocks in TW Market7.9%
10% least volatile stocks in TW Market1.9%

Stable Share Price: 4168 has not had significant price volatility in the past 3 months.

Volatility Over Time: 4168's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2001n/aMei-Chun Yanghttps://www.glyconex.com.tw

GlycoNex Incorporation engages in the development of cancer drugs using glycosphingolipid antigen and human monoclonal antibody technologies in Taiwan. The company’s development pipeline for the treatment of solid tumors includes GNX102, a humanized monoclonal antibody, currently under phase 1 clinical stage; GNX201, an antibody drug currently under lead optimization stage; GNX202, an antibody drug currently under preclinical stage; and GNX203 and GNX204, antibody drugs currently under target validation stage. It is also involved in the development of SPD (Denosumab), a humanized IgG2 antibody that is in preclinical stage for the treatment of osteoporosis and oncology; and SEA (Aflibercept), a vascular endothelial growth factor binding fusion protein, currently under lead optimization stage for the treatment of ophthalmology and oncology.

GlycoNex Incorporation Fundamentals Summary

How do GlycoNex Incorporation's earnings and revenue compare to its market cap?
4168 fundamental statistics
Market capNT$2.67b
Earnings (TTM)-NT$178.36m
Revenue (TTM)NT$2.54m

1,051x

P/S Ratio

-15.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
4168 income statement (TTM)
RevenueNT$2.54m
Cost of RevenueNT$1.55m
Gross ProfitNT$995.00k
Other ExpensesNT$179.36m
Earnings-NT$178.36m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-1.64
Gross Margin39.14%
Net Profit Margin-7,016.60%
Debt/Equity Ratio0%

How did 4168 perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.